Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The transcript "novel transcript, antisense to ANO4" (ENSG00000257325) is a naturally occurring antisense RNA transcribed from the opposite strand of the Anoctamin-4 (ANO4) gene locus. Antisense transcripts typically do not encode proteins but may form double-stranded RNA duplexes with the sense (canonical) mRNA, influencing gene expression levels through multiple mechanisms, including interfering with transcription, affecting chromatin state, or modulating RNA processing and stability[1][3][5]. While natural antisense transcripts are broadly recognized as important modulators of gene expression and epigenetic regulation, most—including this one—are not themselves established as direct therapeutic targets, biomarkers, or disease drivers[2][5]. The specific function, disease relevance, and clinical significance of the antisense transcript to ANO4 remain undetermined.
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural antisense transcript to Anoctamin-4.